PDF(Pubmed)
Abstract：
BACKGROUND: Trastuzumab treatment for salivary gland, gastric, and breast cancer commonly causes cancer treatment-related cardiac dysfunction (CTRCD). CTRCD incidence by sex has not been well studied.
METHODS: This retrospective cohort study investigated frequency of and sex differences in CTRCD in patients with salivary gland cancer treated with trastuzumab at our hospital from April 2017 to March 2022. All patients underwent echocardiography at baseline and after the first, third, and sixth trastuzumab courses. We measured changes in global and regional longitudinal strain (LS) after trastuzumab administration. CTRCD was defined by left ventricular ejection fraction (LVEF) or global LS (GLS). The results were compared by sex.
RESULTS: We recorded clinical data of 49 patients (median age [IQR], 65 [55-71] years; males [75.5%]). The median follow-up period after the sixth trastuzumab course was 120 (111-128) days. One female patient and no male patient had CTRCD defined by LVEF, and two female patients (16.7%) and seven male patients (18.9%) had CTRCD, defined by GLS. The Kaplan-Meier curves showed no significant difference in CTRCD frequency, defined by GLS (log-rank, p = 0.88), between female and male patients. In the univariate analysis, sex was not associated with CTRCD, defined by GLS. A significant difference in apical LS was observed between baseline and the third follow-up results of male patients.
CONCLUSIONS: In this study, CTRCD incidence was not significantly different between male and female patients with salivary gland cancer treated with trastuzumab. Although most previous studies have looked at female patients with breast cancer, a male patient may be found to be at similar risk of myocardial damage.
METHODS: This retrospective cohort study investigated frequency of and sex differences in CTRCD in patients with salivary gland cancer treated with trastuzumab at our hospital from April 2017 to March 2022. All patients underwent echocardiography at baseline and after the first, third, and sixth trastuzumab courses. We measured changes in global and regional longitudinal strain (LS) after trastuzumab administration. CTRCD was defined by left ventricular ejection fraction (LVEF) or global LS (GLS). The results were compared by sex.
RESULTS: We recorded clinical data of 49 patients (median age [IQR], 65 [55-71] years; males [75.5%]). The median follow-up period after the sixth trastuzumab course was 120 (111-128) days. One female patient and no male patient had CTRCD defined by LVEF, and two female patients (16.7%) and seven male patients (18.9%) had CTRCD, defined by GLS. The Kaplan-Meier curves showed no significant difference in CTRCD frequency, defined by GLS (log-rank, p = 0.88), between female and male patients. In the univariate analysis, sex was not associated with CTRCD, defined by GLS. A significant difference in apical LS was observed between baseline and the third follow-up results of male patients.
CONCLUSIONS: In this study, CTRCD incidence was not significantly different between male and female patients with salivary gland cancer treated with trastuzumab. Although most previous studies have looked at female patients with breast cancer, a male patient may be found to be at similar risk of myocardial damage.
摘要：
背景：曲妥珠单抗治疗唾液腺，胃,和乳腺癌通常会导致癌症治疗相关的心功能不全（CTRCD）。CTRCD性别发病率尚未得到很好的研究。
方法：这项回顾性队列研究调查了2017年4月至2022年3月在我院接受曲妥珠单抗治疗的唾液腺癌患者CTRCD的频率和性别差异。所有患者在基线时及术后均接受超声心动图检查,第三,和第六个曲妥珠单抗课程。我们测量了曲妥珠单抗给药后全球和区域纵向应变（LS）的变化。CTRCD由左心室射血分数（LVEF）或全局LS（GLS）定义。结果按性别进行比较。
结果：我们记录了49例患者的临床数据（中位年龄[IQR]，65[55-71]岁；男性[75.5%]）。第六个曲妥珠单抗疗程后的中位随访期为120（111-128）天。一名女性患者和无一名男性患者有LVEF定义的CTRCD，2例女性患者（16.7%）和7例男性患者（18.9%）有CTRCD，由GLS定义。Kaplan-Meier曲线显示CTRCD频率无显著差异，由GLS定义(对数秩，p=0.88),女性和男性患者之间。在单变量分析中，性别与CTRCD无关，由GLS定义。男性患者的基线和第三次随访结果之间观察到根尖LS的显着差异。
结论：在这项研究中，用曲妥珠单抗治疗的男性和女性唾液腺癌患者之间的CTRCD发生率没有显着差异。尽管以前的大多数研究都着眼于女性乳腺癌患者，男性患者可能有类似的心肌损伤风险。
方法：这项回顾性队列研究调查了2017年4月至2022年3月在我院接受曲妥珠单抗治疗的唾液腺癌患者CTRCD的频率和性别差异。所有患者在基线时及术后均接受超声心动图检查,第三,和第六个曲妥珠单抗课程。我们测量了曲妥珠单抗给药后全球和区域纵向应变（LS）的变化。CTRCD由左心室射血分数（LVEF）或全局LS（GLS）定义。结果按性别进行比较。
结果：我们记录了49例患者的临床数据（中位年龄[IQR]，65[55-71]岁；男性[75.5%]）。第六个曲妥珠单抗疗程后的中位随访期为120（111-128）天。一名女性患者和无一名男性患者有LVEF定义的CTRCD，2例女性患者（16.7%）和7例男性患者（18.9%）有CTRCD，由GLS定义。Kaplan-Meier曲线显示CTRCD频率无显著差异，由GLS定义(对数秩，p=0.88),女性和男性患者之间。在单变量分析中，性别与CTRCD无关，由GLS定义。男性患者的基线和第三次随访结果之间观察到根尖LS的显着差异。
结论：在这项研究中，用曲妥珠单抗治疗的男性和女性唾液腺癌患者之间的CTRCD发生率没有显着差异。尽管以前的大多数研究都着眼于女性乳腺癌患者，男性患者可能有类似的心肌损伤风险。
